|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:ATCCode
|
M04AA03
|
|
gptkbp:blackBoxWarning
|
increased risk of cardiovascular death
|
|
gptkbp:brand
|
gptkb:Uloric
Adenuric
|
|
gptkbp:CASNumber
|
144060-53-7
|
|
gptkbp:chemicalFormula
|
C16H16N2O3S
|
|
gptkbp:contraindication
|
severe hepatic impairment
concomitant use with azathioprine
concomitant use with mercaptopurine
|
|
gptkbp:drugClass
|
xanthine oxidase inhibitor
|
|
gptkbp:eliminationHalfLife
|
5-8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
febuxostat
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Uloric
|
|
gptkbp:indication
|
chronic management of hyperuricemia in patients with gout
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:mechanismOfAction
|
xanthine oxidase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
316.37 g/mol
|
|
gptkbp:notRecommendedFor
|
asymptomatic hyperuricemia
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
rash
cardiovascular events
gout flares
liver function abnormalities
|
|
gptkbp:usedFor
|
treatment of gout
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Takeda_(Japan)
|
|
gptkbp:bfsLayer
|
6
|